Our results are in line with previous data on in vitro models in CLL [2, 3, 6], which may be explained by affinity of ibrutinib to interleukin-2-inducible T-cell kinase (ITK), expressed in NK cells, but could also be related to reduced CD20-expression [7, 8]. This evidence concerns the gene ITK and B-cell chronic lymphocytic leukemia.